All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-07-06T12:31:25.000Z

EHA 2018 | Genetic mutations identify patients with poor prognosis in splenic MZL

Jul 6, 2018
Share:

Bookmark this article

On Friday 15th June an oral abstract session took place at the 23rd Congress of the European Hematology Association (EHA). Abstract S103 was presented by Francesca Guidetti, Institute of Oncology Research, Bellinzona, Switzerland, provided an interim analysis of the IELSG46 study. This study aimed to investigate the impact of different biological aspects of splenic marginal zone lymphoma (SMZL) on disease survival.

Dr Guidetti explained that there are 133 genes that are recurrently mutated in SMZL and lymphomas. Molecular genetics have improved the knowledge of MZL pathogenesis and although the disease is indolent, the disease is still incurable. It has been found that molecular features of SMZL associated with prognosis are; immunoglobulin gene mutations, 7q deletion, NOTCH2 mutations, KLF2 mutation and TP53 disruption.

Study Overview

  • More than 30 centers provided spleen tissues of patients diagnosed with SMZL before Dec 31st 2010
  • The relative survival of the study cohort after a median follow-up of 9.2 years was 85% and the median overall survival (OS) was 17.1 years
  • The 10-year relative survival for NOTCH2 and KLF2 (n = 44) was 68.8%, P < 0.001
  • The 10-year relative survival for SPEN and KMT2D (n = 35) was 86.5%, P = 0.311
  • The 10-year relative survival for others (n = 167) was 82.3%, P = 0.092

Dr Guidetti concluded that patients with the TP53 mutation (10%) had a lower probability of OS. Patients with NOTCH2/KLF2 mutations have a lower relative survival compared to the matched general population.

  1. Guidetti F. TP53 Mutations, but not NOTCH2 or KLF2 mutations, identify patients with poor prognosis in splenic marginal zone lymphoma – interim analysis of the IELSG46 study. Abstract S103. 23rd Congress of EHA, Stockholm, Sweden

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox